Almirall to focus on respiratory and skin diseases
Catalan Economy
01 Jan 2010
Pharmaceutical group almirall is to focus its r+d investments on new treatments for respiratory diseases such as asthma and chronic obstructive pulmonary disease (copd) and skin problems, particularly psoriasis and skin cancer.
according to almirall's development director pere berga, the company invested nearly eur 100 million in r&d in 2009. the lab also expects to finalize this year clinical trials for eklira, its new drug for copd. in 2009, almirall posted eur 701 million in revenue, with net profit reaching eur 141 million. the group has a team of 550 researchers at its three centers in sant feliu de llobregat, sant just desvern and sant andreu de la barca (barcelona).
source: expansión 25/01/2010
More News and Success Stories.
-
19 Nov 2026
See more Barcelona ranks second in the EU for artificial intelligence, according to The Observer’s AI Cities IndexBarcelona ranks second in the EU for artificial intelligence, according to The Observer’s AI Cities Index
-
13 Nov 2026
See more ACCIÓ-Catalonia Trade & Investment named a Startup Ecosystem Star 2026ACCIÓ-Catalonia Trade & Investment named a Startup Ecosystem Star 2026
-
04 Nov 2026
See more Catalonia’s silver economy now includes over 1,000 companies and generates more than €13.3 billion in revenueCatalonia’s silver economy now includes over 1,000 companies and generates more than €13.3 billion in revenue
-
29 Oct 2026
See more Catalonia’s cybersecurity sector surpasses €1.7 billion in revenue, growing 19.8%Catalonia’s cybersecurity sector surpasses €1.7 billion in revenue, growing 19.8%

